Medtronic, a global leader in medical technology, announced on February 3, 2026, its intent to fully acquire Israeli medtech company CathWorks. The deal, valued at up to $585 million upfront with potential additional undisclosed earn-out payments, marks the exercise of an acquisition option from a 2022 strategic partnership.
This move strengthens Medtronic’s interventional cardiology portfolio by integrating cutting-edge AI diagnostics for coronary artery disease (CAD), one of the leading causes of death worldwide.
The acquisition builds on a 2022 agreement where Medtronic invested up to $75 million in CathWorks and began co-promoting its flagship product in the U.S., Europe, and Japan. Now, Medtronic is exercising its option to buy the company outright, pending U.S. Federal Trade Commission approval. The transaction is expected to close by the end of Medtronic’s fiscal year 2026.
At the heart of the deal is CathWorks’ FFRangio System, an AI-powered platform that revolutionizes coronary physiology assessment. Traditional fractional flow reserve (FFR) measurements require invasive pressure wires and drug-induced hyperemia, which can be time-consuming and limit adoption.
FFRangio, by contrast, uses artificial intelligence and advanced computational science to derive FFR values directly from routine coronary angiograms (X-rays). It provides a quick, non-invasive, wire-free analysis of the entire coronary tree, helping physicians determine the functional significance of blockages and decide whether stenting is truly needed.
Jason Weidman, senior vice president and president of Medtronic’s Coronary & Renal Denervation business, emphasized the transformative potential: “This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care.”
By combining FFRangio’s diagnostic capabilities with Medtronic’s extensive lineup of interventional tools—like stents and balloons—the company aims to create a more seamless workflow. This could improve patient outcomes by ensuring revascularization only when physiologically necessary, while expanding access to advanced diagnostics through Medtronic’s vast global distribution network.
The deal underscores Medtronic’s strategy of targeted acquisitions to bolster innovation in cardiovascular care, particularly as AI gains traction in healthcare. For CathWorks, headquartered in Kfar Saba, Israel, joining Medtronic accelerates the global scaling of its technology.
As cardiovascular disease remains a top health challenge, this acquisition signals a shift toward smarter, less invasive diagnostics—potentially redefining standards in the catheterization lab.